[{"id":"5960154e-49bc-4681-a851-1b39b31a4731","acronym":"","url":"https://clinicaltrials.gov/study/NCT02983006","created_at":"2021-01-18T14:40:27.968Z","updated_at":"2025-02-25T14:36:58.593Z","phase":"Phase 1","brief_title":"Study of DS-8273a With Nivolumab in Unresectable Stage III or Stage IV Melanoma","source_id_and_acronym":"NCT02983006","lead_sponsor":"NYU Langone Health","biomarkers":" IL2","pipe":"","alterations":" ","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • DS-8273"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 10/01/2016","start_date":" 10/01/2016","primary_txt":" Primary completion: 12/23/2019","primary_completion_date":" 12/23/2019","study_txt":" Completion: 01/01/2021","study_completion_date":" 01/01/2021","last_update_posted":"2021-10-18"}]